Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Celgene Corporation is a drug manufacturers - general business based in the US. Celgene Corporation shares (CELG) are listed on the NASDAQ and all prices are listed in US Dollars. Celgene Corporation employs 8,852 staff and has a trailing 12-month revenue of around $17 billion.
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $108.24 |
| 200-day moving average | $104.36 |
| Wall St. target price | $103.40 |
| PE ratio | 13.33 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $8.13 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Celgene Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Celgene Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
| Revenue TTM | $17 billion |
|---|---|
| Operating margin TTM | 48.75% |
| Gross profit TTM | $14.1 billion |
| Return on assets TTM | 13.69% |
| Return on equity TTM | 69.39% |
| Profit margin | 34.63% |
| Book value | $16.99 |
| Market Capitalization | $77 billion |
TTM: trailing 12 months
We're not expecting Celgene Corporation to pay a dividend over the next 12 months.
Celgene Corporation's shares were split on a 2:1 basis on 25 June 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Celgene Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Celgene Corporation shares which in turn could have impacted Celgene Corporation's share price.
Over the last 12 months, Celgene Corporation's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Celgene Corporation's is 1.4131. This would suggest that Celgene Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc. ; Agios Pharmaceuticals, Inc. ; bluebird bio, Inc.
Learn the basics of call options: what they are, how they work and examples.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
These are the 10 best stocks to buy right now, trading on the Nasdaq and NYSE.
Features and fees to consider before you open an account with this trading platform.
Compare pros, cons, research tools and reviews for these two trading platforms.
What you need to know about investing in the leading indicator for the overall US stock market.
There are many ways to invest and grow $50K depending on your financial situation, personal needs and goals.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.
Check out the best-performing ETFs so far in 2024.